Key Highlights: Implications: For Novartis India, bringing these brands back in‑house supports a more controlled go‑to‑market under new PE ownership and aligns with its plan to insta...
Key Highlights: Implications: If completed, the transaction would likely be a strong validation event for mid-sized Indian pharmaceutical businesses that combine branded generics, nu...
The pharmaceutical industry is entering a new era where innovation is no longer driven by individual organisations alone. From drug discovery and clinical research to manufacturing, regulatory complia...
Key Highlights Implications: Indoco is effectively cashing out of a non-core, lower-scale ophthalmic franchise (₹110 crore slump sale) to refocus capital and management on highe...
